NorthX Biologics, a Stockholm, Sweden-based biopharmaceutical contract, development and manufacturing organization (CDMO), received a growth investment from Signet Healthcare Partners.
The amount of the deal was not disclosed. Following the transaction, James Gale, Managing Director at Signet Healthcare Partners, will join the NorthX Biologics Board of Directors.
The company intends to use the funds to accelerate its expansion plans, enhance facilities, service lines, and extend U.S. commercial reach.
NorthX Biologics is a CDMO and innovation hub in advanced biologics, with +30 years of GMP production experience. It provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics.
The company serves customers worldwide.
FinSMEs
22/05/2025